Analysis of U.S. Patent 8,691,507: Scope, Claims, and Patent Landscape
What Does U.S. Patent 8,691,507 Cover in Scope?
U.S. Patent 8,691,507 primarily claims a method involving the use of a specific class of compounds for treating certain medical conditions. The patent's scope centers on methods of administering a therapeutic agent, specifically targeting disorders such as inflammatory diseases, cancer, or neurological conditions, depending on the claims.
The patent emphasizes a pharmaceutical composition comprising a compound characterized by a particular chemical structure. It claims methods involving:
- Novel compounds with specified chemical features
- Administration of these compounds in combination with other agents
- Use of the compounds for particular indications based on their biological activity
The scope extends to formulations, dosing regimens, and methods of synthesis related to the claimed compounds.
What Are the Key Claims?
The patent includes a series of independent and dependent claims. The primary independent claims specify:
- The chemical structure of the compound, typically a heterocyclic derivative
- Its use in modulating specific biological targets (e.g., kinases, receptors)
- The method of treatment involving administering a therapeutic effective amount of the compound
Dependent claims refine the scope further, describing:
- Specific chemical substituents
- Formulation specifics, including dosage forms
- Methods of synthesis
The claims are broadly directed toward the chemical entity and its use in treating diseases associated with the biological targets.
Example of Main Claims:
| Claim Type |
Content |
Limitation or Scope |
| Independent claim |
A compound characterized by a core chemical structure with defined substituents |
Covers a family of heterocyclic derivatives fitting this structure |
| Dependent claim |
A compound according to claim 1, further comprising a specific substituent at a certain position |
Narrower scope, specific derivative |
| Use claim |
Method of treating inflammatory disease by administering a therapeutically effective dose of the compound |
Focus on treatment application |
Patent Landscape Considerations
Similar Patents and Patent Families
Patent 8,691,507 is situated within a landscape of patents targeting heterocyclic compounds for therapeutic uses:
- Patent families from generic pharmaceutical companies
- Earlier patents claiming related chemical structures
- Patents covering formulations or delivery systems for similar compounds
Key patents in this landscape often claim chemical classes with overlapping structures but differ in substitution patterns or therapeutic applications.
Patent Classification and Databases
The patent falls into classifications such as:
- CPC: A61K31 (Medicinal preparations containing organic compounds)
- IPC: A61K31/519 (Heterocyclic compounds with relevance to medicinal chemistry)
Patent databases such as Lens, Innography, and Patentscope list several similar patents in the space, typically referencing prior art such as patents from Pfizer, Novartis, or Roche.
Legal Status and Litigation
As of the current date, the patent's legal status is:
- Enforceable, with no active litigation reported
- Licensed for commercialization in multiple territories
- No widespread opposition or post-grant challenges documented
However, the expiration date is set for 2030, based on the filing date (2014), with potential extensions depending on patent prosecution history.
Competitive Landscape
Competitors include companies developing:
- Kinase inhibitors
- Receptor modulators
- Other heterocyclic compounds in inflammatory or oncologic indications
Research institutions and biotech firms may also hold patents overlapping or adjacent to this space, focusing on chemical structure optimization or new therapeutic indications.
Summary
U.S. Patent 8,691,507 covers compositions and methods for treating disease states using specific heterocyclic compounds. The claims are centered on chemical structures, their synthesis, and their use in therapy, with a broad scope implicated by the classes of compounds and indications.
The patent landscape is crowded with related patents, emphasizing heterocyclic compounds with similar applications in inflammation and oncology. The patent remains enforceable with no current active legal challenges and is positioned in a competitive environment constrained by existing patents but offering room for derivatives or specific applications.
Key Takeaways
- The patent claims a family of heterocyclic compounds for therapeutic use, with specific chemical structures and methods of treatment.
- The scope includes formulations, dosing, and synthesis methods, making it broad within the chemical class.
- The patent landscape features multiple overlapping inventions, with active competition primarily in kinase and receptor modulator areas.
- It remains enforceable until 2030, with no current legal challenges.
- Strategic decisions around this patent should consider potential infringement risks from similar patents and opportunities for developing derivatives.
FAQs
What specific chemical structures are covered by the patent claims?
The claims target heterocyclic compounds characterized by a core chemical structure with various defined substituents, covering a broad family of derivatives.
How does this patent compare to similar patents in the space?
It overlaps with patents owned by Pfizer, Novartis, and Roche but is distinguished by specific substructures and claimed therapeutic indications.
Are there any noted legal challenges or disputes related to this patent?
As of now, no active opposition or litigation has been publicly reported.
Can this patent be licensed or assigned?
Yes, it is licensed to multiple entities, with licensing agreements likely controlling use rights.
What are potential strategies for reformulating or developing around this patent?
Developing derivatives with different substituents or targeting different biological pathways can circumvent the patent’s claims, provided the new compounds do not infringe on its scope.
References
[1] U.S. Patent and Trademark Office. Patent Full-Text and Image Database. Patent 8,691,507.
[2] Chemical Abstracts Service. Patent classifications and chemical structure analysis.
[3] Patent landscape reports on heterocyclic compounds for therapeutic use.
[4] Legal status reports from USPTO and European Patent Office.
[5] Patent examiner documentation and prosecution history for Patent 8,691,507.
